GlaxoSmithKline says it plans to test its Cervarix vaccine to prevent cervical cancer against Merck's Gardasil in a gamble for GSK to try to overtake Merck sales. GSK said it would conduct a 1,000-patient trial comparing the two drugs, even though Gardasil already is on the market and Cervarix is not expected to be submitted to the FDA for approval until 2009. The American Cancer Society today is expected to announce its recommendation that HPV vaccinations be routine for all girls as young as 11.

Full Story:

Related Summaries